Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Chimerix
January 27, 2017
Upcoming events – Late-stage data from Trevena and Chimerix
August 15, 2016
Therapy focus – Hepatitis B developers try to repeat Gilead’s hep C trick
January 07, 2016
Wobbles aside, small pharma shares broadly on the up in 2015
January 04, 2016
Pharma regulatory and development news over Christmas
October 22, 2014
Bavarian Nordic leaps ahead in Ebola race
March 20, 2014
Circassia joins the exclusive $100m+ IPO club
January 06, 2014
Fast times in biotech push IPO count to new highs
December 17, 2013
Vantage Point – Under pressure to return profits, venture funds raise new money
July 10, 2013
Floats rise out of the biotech bubble at last
May 29, 2013
IPO flurry raises valuation gap questions
February 13, 2013
Product deal values continue to head south in 2012
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 17, 2019
Vantage 2020 Preview
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Editor's Picks
January 28, 2020
The cost to Astrazeneca of building Brilinta
January 27, 2020
Rare diseases top another strong year for novel drug approvals
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
January 16, 2020
A quiet six months for device approvals
January 22, 2020
Sanofi's geriatric pipeline fails to freshen up
